Sugi Predict

Sugi Predict / Compounds / SCHEMBL15067937

SCHEMBL15067937

SCHEMBL15067937

Cc1c(Br)cn(C)c(=O)c1[N+](=O)[O-]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 3/20 0.43
▸ GRIN3B O60391 3/20 0.43
▸ GRIN1 Q05586 3/20 0.43
▸ GRIN2A Q12879 3/20 0.43
▸ GRIN2B Q13224 3/20 0.43
▸ GRIN2C Q14957 3/20 0.43
▸ GRIN3A Q8TCU5 3/20 0.43
▸ MAPT P10636 5/20 0.38
▸ NPSR1 Q6W5P4 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ NPC1 O15118 1/20 0.33
▸ XBP1 P17861 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20155036 0.81 MAPT (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20155561 0.81 ALDH1A1 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22553952 0.74 GRIN2D (0.38) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL16650601 0.74 BRD4 (0.34) —
SCHEMBL31440040 0.73 GAA (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15964511 0.72 LMNA (0.36) MAPTNPSR1LMNAKDM4EHTT
SCHEMBL22554172 0.72 MEN1 (0.48) MAPTNPSR1LMNAHTTALDH1A1
SCHEMBL20545386 0.71 KDM4E (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL22990247 0.69 MAP2K1 (0.35) —
SCHEMBL20704658 0.69 BRD4 (0.33) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040445-A Heterocyclopyridine-7-one compound and medical application thereof 浙江大学金华研究院 2025-05-27 — — CN disclosed
CN-114401964-B Compound with BRD4 inhibitory activity, preparation method and application thereof 上海海和药物研究开发股份有限公司 2024-10-01 — — CN disclosed
US-20240150328-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS FOGHORN THERAPEUTICS INC. 2024-05-09 — — US disclosed
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2024-05-09 — — US disclosed
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors HIBERCELL, INC. (US) 2024-03-05 — — US disclosed
WO-2024027712-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 索智生物科技（浙江）有限公司 2024-02-08 — — WO disclosed
CN-117486861-A Nitrogen-containing heterocyclic compound, preparation method and application thereof 索智生物科技（浙江）有限公司 2024-02-02 — — CN disclosed
CN-112088157-B Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors 拉文纳制药公司 2023-12-26 — — CN disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 — — US disclosed
US-11773085-B2 Methods and compounds for treating disorders FOGHORN THERAPEUTICS INC. (US) 2023-10-03 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS INCYTE CORPORATION (US) 2015-05-28 — — US disclosed
EP-2797918-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2014-11-05 — — EP disclosed
WO-2014125408-A2 SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-21 — — WO disclosed
WO-2014125408-A2 SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-08-21 — — WO disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 — — US disclosed
WO-2013097601-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2013-07-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148375-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 GRIN2D 2026/4885GRIN3B 3257/4885GRIN1 3221/4885
US-20240150343-A1 COMPOUND HAVING BRD4 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF BRD4, BICRA, BET1 GRIN2D 3702/4885GRIN3B 2392/4885GRIN1 1077/4885
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 GRIN2D 2768/4885GRIN3B 1887/4885GRIN1 617/4885
US-11919902-B2 Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors PIP5K1A, PIP5K1B, PIP5K1C GRIN2D 1748/4885GRIN3B 2587/4885GRIN1 1572/4885
US-11773085-B2 Methods and compounds for treating disorders VHL, TFEB, BECN1 GRIN2D 4696/4885GRIN3B 4198/4885GRIN1 4244/4885
US-20240150328-A1 METHODS AND COMPOUNDS FOR TREATING DISORDERS VHL, TFEB, BECN1 GRIN2D 4696/4885GRIN3B 4198/4885GRIN1 4244/4885
US-20150148342-A1 BICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS BRD1, BRD3, BRD2 GRIN2D 2026/4885GRIN3B 3257/4885GRIN1 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.